solifenacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
muscarinic receptors antagonists	2457	242478-37-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: YM-67905 YM-905 solifenacin solifenacin succinate vesicare	A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE. Molecular weight: 362.47 Formula: C23H26N2O2 CLOGP: 4.68 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 32.78 ALOGS: -3.70 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

YM-67905
YM-905
solifenacin
solifenacin succinate
vesicare

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Molecular weight: 362.47
Formula: C23H26N2O2
CLOGP: 4.68
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 32.78
ALOGS: -3.70
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	8.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	52 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 19, 2004	FDA	ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dry mouth	197.77	11.35	179	22505	55999	50526441
Multiple sclerosis relapse	126.43	11.35	124	22560	42840	50539600
Urinary retention	111.36	11.35	93	22591	26097	50556343
Fall	105.96	11.35	360	22324	334572	50247868
Urinary incontinence	71.25	11.35	75	22609	28133	50554307
Urinary tract infection	67.35	11.35	237	22447	223783	50358657
Vision blurred	64.88	11.35	122	22562	78525	50503915
Residual urine volume increased	62.43	11.35	11	22673	20	50582420
Gait disturbance	57.03	11.35	172	22512	149833	50432607
Multiple sclerosis	52.66	11.35	55	22629	20438	50562002
Fear of eating	49.44	11.35	14	22670	326	50582114
Dementia	48.57	11.35	47	22637	15950	50566490
Maternal exposure during pregnancy	48.44	11.35	7	22677	159771	50422669
Arteriovenous fistula occlusion	47.94	11.35	14	22670	365	50582075
Blue toe syndrome	46.99	11.35	14	22670	392	50582048
Constipation	45.41	11.35	184	22500	185524	50396916
Drug intolerance	40.52	11.35	24	22660	219080	50363360
Contraindicated product administered	37.86	11.35	10	22674	148948	50433492
Hallucination	36.75	11.35	71	22613	46586	50535854
Synovitis	36.23	11.35	6	22678	123859	50458581
Lymphocyte count decreased	35.51	11.35	51	22633	26256	50556184
Hand deformity	33.84	11.35	3	22681	100196	50482244
Cerebellar syndrome	33.51	11.35	20	22664	3291	50579149
Cutaneous T-cell dyscrasia	30.89	11.35	7	22677	63	50582377
Cutaneous lupus erythematosus	30.80	11.35	17	22667	2414	50580026
Infusion related reaction	30.74	11.35	19	22665	169538	50412902
Renal pain	30.40	11.35	23	22661	5596	50576844
Treatment failure	30.10	11.35	12	22672	137625	50444815
Bladder sphincter atony	29.55	11.35	8	22676	157	50582283
Balance disorder	28.74	11.35	83	22601	70507	50511933
Dry throat	28.33	11.35	22	22662	5562	50576878
Nodular rash	27.83	11.35	8	22676	197	50582243
Confusional state	27.17	11.35	159	22525	185769	50396671
Toxicity to various agents	26.31	11.35	34	22650	212465	50369975
Discomfort	26.19	11.35	8	22676	108372	50474068
Exposure during pregnancy	25.74	11.35	11	22673	121004	50461436
Glossodynia	25.39	11.35	10	22674	115559	50466881
Sinus arrest	24.66	11.35	13	22671	1685	50580755
Bladder disorder	24.49	11.35	23	22661	7520	50574920
Dysuria	24.46	11.35	45	22639	28459	50553981
Disorientation	24.36	11.35	51	22633	35433	50547007
Swelling	23.99	11.35	33	22651	200839	50381601
Therapeutic product effect decreased	23.62	11.35	16	22668	136034	50446406
Sinus node dysfunction	23.21	11.35	17	22667	3938	50578502
Cystitis	22.77	11.35	57	22627	44507	50537933
Poliomyelitis	21.87	11.35	5	22679	47	50582393
Pyelonephritis	21.62	11.35	30	22654	14959	50567481
Rheumatoid arthritis	21.56	11.35	36	22648	202514	50379926
Dyskinesia	21.45	11.35	42	22642	27819	50554621
Joint swelling	21.43	11.35	49	22635	245237	50337203
Dyspepsia	21	11.35	77	22607	74020	50508420
Renal function test abnormal	20.80	11.35	14	22670	2835	50579605
Hallucination, visual	20.72	11.35	31	22653	16551	50565889
Pericarditis	20.53	11.35	5	22679	78684	50503756
Hypertonic bladder	20.15	11.35	14	22670	2986	50579454
Muscular weakness	19.98	11.35	90	22594	94923	50487517
Malaise	19.10	11.35	232	22452	335300	50247140
Heat stroke	18.88	11.35	8	22676	635	50581805
Micturition urgency	17.44	11.35	20	22664	8244	50574196
Dizziness	17.39	11.35	234	22450	346135	50236305
Hyponatraemia	17.26	11.35	87	22597	96052	50486388
Lower urinary tract symptoms	17.09	11.35	4	22680	42	50582398
Oscillopsia	16.99	11.35	5	22679	134	50582306
Pain	16.93	11.35	172	22512	578731	50003709
Colitis ischaemic	16.80	11.35	21	22663	9462	50572978
Off label use	16.40	11.35	301	22383	474125	50108315
Neurogenic bladder	16.13	11.35	12	22672	2845	50579595
Torsade de pointes	16.05	11.35	23	22661	11812	50570628
Thalamus haemorrhage	15.97	11.35	7	22677	603	50581837
Hepatic enzyme increased	15.96	11.35	23	22661	137357	50445083
Incontinence	15.94	11.35	21	22663	9964	50572476
Upper gastrointestinal haemorrhage	15.93	11.35	27	22657	16008	50566432
Lower respiratory tract infection	15.47	11.35	12	22672	95189	50487251
Dry eye	15.30	11.35	40	22644	32055	50550385
Drug abuse	15.23	11.35	4	22680	59842	50522598
Wound	15.18	11.35	15	22669	105779	50476661
Labelled drug-drug interaction medication error	15.16	11.35	21	22663	10456	50571984
Benign renal neoplasm	14.76	11.35	3	22681	15	50582425
Visual impairment	14.59	11.35	65	22619	68210	50514230
Blood viscosity increased	14.45	11.35	5	22679	228	50582212
Arthropathy	14.22	11.35	31	22653	157875	50424565
Varicose ulceration	13.81	11.35	6	22678	506	50581934
Vasculitic rash	13.80	11.35	8	22676	1247	50581193
Pollakiuria	13.78	11.35	32	22652	23819	50558621
Memory impairment	13.67	11.35	71	22613	79289	50503151
Language disorder	13.57	11.35	9	22675	1779	50580661
Atrial fibrillation	13.56	11.35	85	22599	101660	50480780
Wrong technique in product usage process	13.53	11.35	55	22629	55455	50526985
Cognitive disorder	13.48	11.35	47	22637	44076	50538364
Abdominal discomfort	13.31	11.35	56	22628	231585	50350855
Subacute hepatic failure	13.10	11.35	4	22680	122	50582318
Poverty of speech	12.89	11.35	5	22679	316	50582124
Cerebral haematoma	12.81	11.35	11	22673	3200	50579240
Escherichia urinary tract infection	12.37	11.35	19	22665	10376	50572064
Posture abnormal	12.30	11.35	9	22675	2080	50580360
Hereditary angioedema with C1 esterase inhibitor deficiency	12.23	11.35	3	22681	39	50582401
Inappropriate schedule of product administration	12.19	11.35	64	22620	71767	50510673
Nodal rhythm	12.07	11.35	8	22676	1579	50580861
JC polyomavirus test positive	12.01	11.35	7	22677	1102	50581338
Hyperthermia	12.00	11.35	16	22668	7680	50574760
Lip swelling	11.97	11.35	31	22653	24705	50557735
Delirium	11.94	11.35	41	22643	38151	50544289
Urge incontinence	11.92	11.35	6	22678	707	50581733
Acute kidney injury	11.80	11.35	155	22529	227903	50354537
Febrile neutropenia	11.69	11.35	16	22668	97651	50484789
Airway remodelling	11.48	11.35	3	22681	51	50582389
Muscle strain	11.46	11.35	15	22669	7073	50575367

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dry mouth	94.18	15.01	69	9731	21715	29543012
Urinary retention	90.71	15.01	79	9721	31819	29532908
Confusional state	78.79	15.01	147	9653	127730	29436997
Hallucination	63.27	15.01	76	9724	44636	29520091
Constipation	56.71	15.01	120	9680	114040	29450687
Fall	52.71	15.01	153	9647	177025	29387702
Urinary incontinence	31.86	15.01	33	9767	16448	29548279
Duplicate therapy error	29.41	15.01	7	9793	110	29564617
Urosepsis	29.28	15.01	26	9774	10720	29554007
Urinary tract infection	29.09	15.01	70	9730	72284	29492443
Gastrointestinal hypomotility	29.07	15.01	11	9789	882	29563845
Hallucination, visual	28.91	15.01	30	9770	14985	29549742
Bladder cancer	28.59	15.01	25	9775	10102	29554625
Epilepsy	27.14	15.01	32	9768	18400	29546327
Hyponatraemia	25.66	15.01	64	9736	67569	29497158
Delirium	25.05	15.01	46	9754	39351	29525376
Dysuria	23.65	15.01	33	9767	22407	29542320
Enterocolitis bacterial	23.59	15.01	7	9793	264	29564463
Product name confusion	21.75	15.01	5	9795	67	29564660
Hypertonic bladder	20.80	15.01	10	9790	1446	29563281
Duodenitis haemorrhagic	20.37	15.01	5	9795	90	29564637
Bladder discomfort	19.60	15.01	5	9795	106	29564621
Pollakiuria	19.52	15.01	26	9774	16890	29547837
Haematuria	19.13	15.01	44	9756	44095	29520632
Somnolence	18.75	15.01	71	9729	93884	29470843
Malaise	18.67	15.01	103	9697	159499	29405228
Pneumonia aspiration	18.62	15.01	39	9761	36698	29528029
Dementia	18.43	15.01	21	9779	11637	29553090
Upper respiratory tract irritation	18.38	15.01	4	9796	41	29564686
Cognitive disorder	18.28	15.01	30	9770	23469	29541258
Body temperature decreased	18.22	15.01	20	9780	10644	29554083
Blood pressure systolic increased	18.09	15.01	25	9775	16820	29547907
Off label use	18.06	15.01	165	9635	300635	29264092
Completed suicide	17.89	15.01	4	9796	90242	29474485
Incontinence	17.46	15.01	14	9786	5018	29559709
Micturition urgency	17.12	15.01	14	9786	5159	29559568
Polyuria	16.54	15.01	16	9784	7346	29557381
Lower urinary tract symptoms	16.33	15.01	5	9795	210	29564517
Foetal heart rate disorder	16.19	15.01	4	9796	74	29564653
On and off phenomenon	15.45	15.01	9	9791	1919	29562808
Cataract	15.33	15.01	27	9773	22351	29542376
Dizziness	15.10	15.01	111	9689	189573	29375154

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dry mouth	154.12	11.35	155	26330	60263	64411984
Fall	134.84	11.35	426	26059	416400	64055847
Urinary retention	123.22	11.35	125	26360	49076	64423171
Multiple sclerosis relapse	98.44	11.35	102	26383	41033	64431214
Confusional state	79.74	11.35	262	26223	260882	64211365
Urinary tract infection	71.26	11.35	233	26252	231363	64240884
Hallucination	69.98	11.35	115	26370	72673	64399574
Urinary incontinence	69.68	11.35	80	26405	36071	64436176
Constipation	64.59	11.35	224	26261	229113	64243134
Fear of eating	61.42	11.35	17	26468	398	64471849
Multiple sclerosis	58.46	11.35	54	26431	18887	64453360
Vision blurred	53.48	11.35	116	26369	90200	64382047
Arteriovenous fistula occlusion	52.43	11.35	16	26469	533	64471714
Residual urine volume increased	52.00	11.35	9	26476	16	64472231
Gait disturbance	46.57	11.35	166	26319	171989	64300258
Toxicity to various agents	45.88	11.35	49	26436	363464	64108783
Blue toe syndrome	43.32	11.35	14	26471	564	64471683
Malaise	41.20	11.35	291	26194	395956	64076291
Hyponatraemia	40.94	11.35	144	26341	148195	64324052
Drug abuse	39.97	11.35	4	26481	132370	64339877
Hallucination, visual	38.24	11.35	52	26433	27782	64444465
Dysuria	35.84	11.35	63	26422	41994	64430253
Renal pain	34.23	11.35	26	26459	6948	64465299
Disorientation	32.23	11.35	71	26414	55757	64416490
Cutaneous T-cell dyscrasia	31.50	11.35	7	26478	63	64472184
Cutaneous lupus erythematosus	30.63	11.35	17	26468	2665	64469582
Dyskinesia	29.75	11.35	56	26429	39332	64432915
Hypertonic bladder	29.33	11.35	18	26467	3400	64468847
Dizziness	29.17	11.35	287	26198	429876	64042371
Dementia	28.84	11.35	39	26446	20727	64451520
Lower urinary tract symptoms	28.64	11.35	8	26477	194	64472053
Balance disorder	28.08	11.35	87	26398	83839	64388408
Cerebellar syndrome	27.53	11.35	20	26465	4996	64467251
Delirium	27.23	11.35	76	26409	69118	64403129
Incontinence	27.18	11.35	29	26456	12052	64460195
Infusion related reaction	25.78	11.35	18	26467	164449	64307798
Gastrointestinal hypomotility	25.48	11.35	13	26472	1720	64470527
Cystitis	25.46	11.35	55	26430	42620	64429627
Nodular rash	25.00	11.35	8	26477	312	64471935
Bladder cancer	24.08	11.35	26	26459	10948	64461299
Treatment failure	23.94	11.35	9	26476	116807	64355440
Duplicate therapy error	23.93	11.35	7	26478	201	64472046
Pollakiuria	22.79	11.35	44	26441	31486	64440761
Poliomyelitis	22.21	11.35	5	26480	48	64472199
Sinus node dysfunction	22.11	11.35	20	26465	6808	64465439
Systemic lupus erythematosus	21.80	11.35	3	26482	77609	64394638
Micturition urgency	21.79	11.35	24	26461	10335	64461912
Synovitis	21.39	11.35	7	26478	99083	64373164
Urosepsis	21.34	11.35	35	26450	22059	64450188
Dyspepsia	21.31	11.35	77	26408	80235	64392012
Bladder discomfort	21.26	11.35	8	26477	508	64471739
Neurogenic bladder	21.17	11.35	15	26470	3604	64468643
Sinus arrest	20.89	11.35	14	26471	3076	64469171
Maternal exposure during pregnancy	20.30	11.35	7	26478	95877	64376370
Renal function test abnormal	19.91	11.35	15	26470	3959	64468288
Epilepsy	19.75	11.35	43	26442	33488	64438759
Upper respiratory tract irritation	18.91	11.35	5	26480	98	64472149
Completed suicide	18.82	11.35	40	26445	224374	64247873
Liver function test abnormal	18.42	11.35	60	26425	59341	64412906
Cognitive disorder	18.32	11.35	57	26428	55030	64417217
Freezing phenomenon	18.21	11.35	10	26475	1536	64470711
Enterocolitis bacterial	17.99	11.35	7	26478	487	64471760
Dry throat	17.75	11.35	17	26468	6215	64466032
Memory impairment	17.75	11.35	76	26409	85606	64386641
Duodenitis haemorrhagic	17.64	11.35	5	26480	128	64472119
Muscular weakness	17.17	11.35	100	26385	127238	64345009
Product name confusion	16.61	11.35	5	26480	159	64472088
Hand deformity	16.33	11.35	3	26482	62768	64409479
Lymphocyte count decreased	16.30	11.35	45	26440	40654	64431593
Pyelonephritis	16.20	11.35	27	26458	17239	64455008
Haematuria	16.06	11.35	58	26427	60413	64411834
On and off phenomenon	16.04	11.35	11	26474	2508	64469739
Oscillopsia	16.04	11.35	5	26480	179	64472068
Cystitis interstitial	15.23	11.35	8	26477	1124	64471123
Therapeutic product effect decreased	15.14	11.35	15	26470	115336	64356911
Thalamus haemorrhage	15.12	11.35	9	26476	1610	64470637
Neutropenia	14.59	11.35	50	26435	239574	64232673
Somnolence	14.31	11.35	137	26348	203508	64268739
Benign renal neoplasm	14.17	11.35	3	26482	21	64472226
Blood viscosity increased	13.89	11.35	5	26480	280	64471967
Pain	13.84	11.35	153	26332	553358	63918889
Labelled drug-drug interaction medication error	13.81	11.35	29	26456	22033	64450214
Acute disseminated encephalomyelitis	13.64	11.35	5	26480	295	64471952
Rheumatoid arthritis	13.18	11.35	30	26455	164264	64307983
Loss of consciousness	13.12	11.35	105	26380	148260	64323987
Oral mucosal eruption	13.04	11.35	6	26479	633	64471614
Bladder disorder	13.00	11.35	16	26469	7751	64464496
Arthralgia	12.81	11.35	118	26367	442142	64030105
Mucosal inflammation	12.52	11.35	5	26480	62579	64409668
Pericarditis	12.50	11.35	5	26480	62511	64409736
Atrial fibrillation	12.47	11.35	116	26369	170973	64301274
Electrocardiogram QT prolonged	12.45	11.35	65	26420	79383	64392864
Stoma site pain	12.44	11.35	7	26478	1126	64471121
Hereditary angioedema with C1 esterase inhibitor deficiency	12.42	11.35	3	26482	40	64472207
Drug hypersensitivity	12.30	11.35	53	26432	237762	64234485
Drug intolerance	12.29	11.35	38	26447	187954	64284293
Lactic acidosis	12.13	11.35	5	26480	61405	64410842
Acute kidney injury	12.13	11.35	255	26230	448985	64023262
Tenoplasty	12.10	11.35	3	26482	45	64472202
Cerebral ventricular rupture	12.01	11.35	5	26480	415	64471832
Genital pain	11.85	11.35	5	26480	429	64471818
Secondary progressive multiple sclerosis	11.84	11.35	7	26478	1236	64471011
Escherichia urinary tract infection	11.53	11.35	19	26466	12018	64460229
Pseudomembranous colitis	11.41	11.35	12	26473	4904	64467343

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD08	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
ATC	G04CA53	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Torsades de pointes	contraindication	31722008
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastrointestinal hypomotility	contraindication	421807004
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1MG/ML	VESICARE LS	ASTELLAS	N209529	May 26, 2020	RX	SUSPENSION	ORAL	May 26, 2023	NEW PRODUCT
1MG/ML	VESICARE LS	ASTELLAS	N209529	May 26, 2020	RX	SUSPENSION	ORAL	Nov. 26, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	IC50	6.88	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	IC50	6.24	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	7.20	IUPHAR
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	7.20	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	6.80	IUPHAR
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	6.92	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	8	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8	CHEMBL

External reference:

ID	Source
4024390	VUID
N0000022393	NUI
D01269	KEGG_DRUG
242478-38-2	SECONDARY_CAS_RN
4021510	VANDF
4024390	VANDF
C1099677	UMLSCUI
CHEBI:135530	CHEBI
CHEMBL1734	ChEMBL_ID
CHEMBL1200803	ChEMBL_ID
DB01591	DRUGBANK_ID
D000069464	MESH_DESCRIPTOR_UI
154059	PUBCHEM_CID
7483	IUPHAR_LIGAND_ID
8155	INN_ID
A8910SQJ1U	UNII
322167	RXNORM
19082	MMSL
256920	MMSL
63797	MMSL
d05413	MMSL
008712	NDDF
008713	NDDF
407030007	SNOMEDCT_US
407031006	SNOMEDCT_US
426324001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Solifenacin succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3795	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Solifenacin succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3795	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Solifenacin succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3796	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Solifenacin succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3796	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
solifenacin succinate	Human Prescription Drug Label	1	27241-037	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
solifenacin succinate	Human Prescription Drug Label	1	27241-038	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-328	TABLET, FILM COATED	5 mg	ORAL	ANDA	19 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-329	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	35561-285	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	35561-286	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-739	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-740	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Solifenacin Succinate	Human Prescription Drug Label	1	46708-192	TABLET, COATED	5 mg	ORAL	ANDA	27 sections
Solifenacin Succinate	Human Prescription Drug Label	1	46708-193	TABLET, COATED	10 mg	ORAL	ANDA	27 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	50228-427	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	50228-428	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	51248-150	TABLET, FILM COATED	5 mg	ORAL	NDA	26 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	51248-150	TABLET, FILM COATED	5 mg	ORAL	NDA	26 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	51248-151	TABLET, FILM COATED	10 mg	ORAL	NDA	26 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	51248-151	TABLET, FILM COATED	10 mg	ORAL	NDA	26 sections
VESIcareLS	HUMAN PRESCRIPTION DRUG LABEL	1	51248-250	SUSPENSION	1 mg	ORAL	NDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-227	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-228	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-254	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-255	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-471	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
SOLIFENACIN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-472	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4705	TABLET, FILM COATED	10 mg	ORAL	NDA	26 sections
VESIcare	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5398	TABLET, FILM COATED	5 mg	ORAL	NDA	26 sections
Solifenacin Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4702	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections